2024
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression
Chepke C, Shelton R, Sanacora G, Doherty T, Tsytsik P, Parker N. Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression. The International Journal Of Neuropsychopharmacology 2024, pyae058. PMID: 39611487, DOI: 10.1093/ijnp/pyae058.Peer-Reviewed Original ResearchEsketamine nasal sprayRespiratory depressionAdverse eventsTreatment of treatment-resistant depressionStandardized Medical Dictionary for Regulatory ActivitiesPhase 3 clinical trialsTreatment-resistant depressionMitigation Strategy programCentral respiratory depressionTreatment of depressive symptomsAcute suicidal ideationPostdose observation periodNo adverse eventsMedical Dictionary for Regulatory ActivitiesOral antidepressantNasal sprayCases meeting criteriaDepressive disorderPostmarketing settingPostapproval dataSuicidal ideationDepressive symptomsOxygen saturationPulse oximetryCase definitionThe genetics of severe depression
Franklin C, Achtyes E, Altinay M, Bailey K, Bhati M, Carr B, Conroy S, Husain M, Khurshid K, Lencz T, McDonald W, Mickey B, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti I, Selek S, Sanacora G, Trapp N, Viswanath B, Wright J, Sullivan P, Zandi P, Potash J. The genetics of severe depression. Molecular Psychiatry 2024, 1-10. PMID: 39406997, DOI: 10.1038/s41380-024-02731-1.Peer-Reviewed Original ResearchGenome-wide association studiesSevere depressionGenome-wide significant lociWhole-exome sequencing studiesAssociated with dysphoriaGenome-wide lociGenome-wide interrogationExome sequencing studiesEarly-onset illnessDegree of impairmentDepressive disorderMDD phenotypesSignificant lociAssociation studiesClinical markers of severitySequencing studiesMDDLociRare variantsClinically actionable findingsEstimates of heritabilityDepressionFamily-basedSevere formGenetics
2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSheehan Disability Scale scoresAdverse eventsDisability scale scorePsilocybin treatmentDay 43Scale scoreSecondary outcomesSingle doseDepressive disorderExclusion criteriaPsychological supportMontgomery-Asberg Depression Rating Scale scoreSerious treatment-emergent adverse eventsDay 8Key secondary outcome measuresTreatment-emergent adverse eventsDepression Rating Scale scoresActive substance use disorderFifth Edition diagnosisIdentical-appearing capsulesOverall adverse eventsPhase 2 trialSerious adverse eventsSevere adverse events
2022
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Feeney A, Hoeppner B, Freeman M, Flynn M, Iosifescu D, Trivedi M, Sanacora G, Mathew S, DeBattista C, Ionescu D, Cusin C, Papakostas G, Jha M, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. The Journal Of Clinical Psychiatry 2022, 84 PMID: 36383742, DOI: 10.4088/jcp.22m14491.Peer-Reviewed Original ResearchConceptsMajor depressive disorderDifferential treatment responsePrimary outcome measureBenzodiazepine useOral benzodiazepinesTreatment responseDay 1Antidepressant effectsHigh dosesClinical Global Impressions-SeverityHamilton Depression Rating ScaleStudy's primary outcome measureIllness Scale scoresTreatment-resistant depressionRandomized clinical trialsDepression Rating ScaleBenzodiazepine dosageIntravenous ketamineConcomitant benzodiazepinesSingle infusionClinical trialsDepressive disorderKetamine studiesOutcome measuresBenzodiazepine effectsDifferences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMetabotropic glutamate receptor 5Glutamate receptor 5MGluR5 availabilityBipolar disorderPositron emission tomographyHC groupDepressive disorderReceptor 5Emission tomographyHealthy control individualsPossible treatment targetsGlutamate transmissionBD depressionTreatment strategiesBD groupMGluR5Depressive symptomsNovel treatmentsCognitive alterationsTreatment targetsSynaptic plasticityControl individualsAccurate diagnosisSignificant negative correlation
2019
Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
Sanacora G, Kitay B, Wilkinson S. Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. 2019, 401-413. DOI: 10.1016/b978-0-12-813333-0.00035-4.Peer-Reviewed Original ResearchAntidepressant actionRapid onsetRapid-onset antidepressant actionRapid acting antidepressantsMajor depressive episodeClear unmet needActing antidepressantsAntidepressant treatmentDepressive episodeKetamine effectsClinical trialsDepressive disorderPreclinical studiesUnmet needSuch treatmentTreatmentComplicating factors
2012
Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting. Journal Of Ect 2012, 28: 157-161. PMID: 22847373, PMCID: PMC3426617, DOI: 10.1097/yct.0b013e31824f8296.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnesthesiaAnesthetics, DissociativeAntidepressive AgentsBipolar DisorderCombined Modality TherapyDepressionDepressive Disorder, MajorElectroconvulsive TherapyElectroencephalographyFemaleHumansHypnotics and SedativesKetamineMaleMiddle AgedPsychiatric Status Rating ScalesSeizuresThiopentalTreatment OutcomeYoung AdultConceptsHamilton Depression Rating ScaleAntidepressant effectsElectroconvulsive therapyECT sessionsDepressive episodeN-methyl-D-aspartate receptor antagonist ketamineN-methyl-D-aspartate antagonistsCoadministration of ketamineFirst ECT sessionRapid antidepressant effectsSevere depressive episodeSignificant antidepressant effectMajor depressive episodeDepression Rating ScaleMajor depressive disorderSixth ECT sessionSignificant group effectImmediate antidepressant effectECT treatmentAntidepressant propertiesHDRS scoresDepressive disorderLow doseBipolar disorderKetamine
2011
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS
Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Research 2011, 191: 122-127. PMID: 21232924, PMCID: PMC3061550, DOI: 10.1016/j.pscychresns.2010.10.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive AgentsBlood PressureDepressive Disorder, MajorDissociative DisordersFemaleGamma-Aminobutyric AcidGlutamic AcidHeart RateHumansKetamineMagnetic Resonance SpectroscopyMaleMiddle AgedOccipital LobeProtonsPsychiatric Status Rating ScalesPsychometricsRetrospective StudiesSingle-Blind MethodStatistics as TopicTime FactorsYoung AdultConceptsMajor depressive disorderAntidepressant effectsAntidepressant actionNeurotransmitter contentNMDA receptor antagonist ketamineProton magnetic resonance spectroscopy methodConventional antidepressant treatmentKetamine's antidepressant actionSingle intravenous doseSingle-blind conditionsAntidepressant treatmentChronic treatmentKetamine infusionIntravenous dosePharmacodynamic basisDepressive disorderAcute actionsMRS scansOccipital cortexDepressive symptomsDepression scoresRating ScaleBaseline measuresInfusionKetamine
2008
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.Peer-Reviewed Original ResearchConceptsGlutamatergic systemMood disordersAntidepressant effectsNMDA antagonistsDouble-blind placebo-controlled crossover studyTreatment-resistant major depressive disorderPlacebo-controlled crossover studyGlutamate release inhibitorSignificant antidepressant effectNMDA receptor expressionRecurrent mental illnessSingle intravenous doseMajor depressive disorderPotential novel therapeuticsGlutamatergic abnormalitiesCrossover studyGlutamate releaseIntravenous doseMood stabilizersDepressive disorderReceptor expressionReceptor modulatorsEvidence of alterationsCerebrospinal fluidAMPA potentiators
2002
Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders
Sanacora G. Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders. 2002, 739-749. DOI: 10.1002/0470854871.chxviii3.Peer-Reviewed Original ResearchGlutamatergic abnormalitiesGlutamatergic effectsGABAergic abnormalitiesMood stabilizersAnimal modelsGABAergic contributionGABA's roleDepression EvidenceGlutamatergic involvementDepressive disorderAntidepressantsAbnormalitiesNMDAGABAReference evidenceTreatmentNeurobiologyEvidenceEffect evidenceGABAergicPathophysiologyRole